| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Immune-mediated central nervous system (CNS) disorders, including neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein (MOG-IgG) associated disease (MOGAD), present with similar clinical and radiologic features as multiple sclerosis, which is the most common CNS demyelinating disease. Because multiple sclerosis treatment may worsen NMOSD and MOGAD, accurate diagnosis is critical.
10-15%
10-15% of positive MOG cases could be missed by commercial fixed MOG-IgG assay1
1/3
1/3 of AQP4-IgG-negative patients are positive for MOG-IgG2
50%
50% probability of second optic neuritis episode within one year of initial attack in AQP4-positive patients3
CNS demyelinating disease Test menu
Our unique evaluation to diagnose immune-mediated CNS demyelinating disease uses a fluorescence activated cell sorting (FACS) live cell-binding assay to detect the two most common antibodies linked to the harmful autoimmune response. Identification of aquaporin-4 (AQP4-IgG) and MOG-IgG allows for diagnostic certainty and implementation of an appropriate treatment regimen, which minimizes the risk of relapse and patient disability.
Key testing
Advantages
Highlights
In this month's "Hot Topic," Eoin Flanagan, M.B., B.Ch., reviews the recent diagnostic criteria for Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD).
Lying in an ICU bed as sick as he could get, Jon Bratsch thought he was past the point of no return. But when a Mayo Clinic Laboratories’ test revealed the source of his dire symptoms, everything changed. Today, Jon’s back to the life and family he loves.
In this month’s “Hot Topic,” Sean Pittock, M.D., explains Neuromyelitis Optica Spectrum Disorder (NMOSD) and the critical importance of a sensitive and specific AQP4-IgG laboratory test for early diagnosis and treatment.